This is a preview of subscription content, log in via an institution to check access.
References
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–2405.
Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241–247.
Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616–3627.
Bejar R, Levine R, Ebert BL . Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011; 29: 504–515.
Haase D . Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008; 87: 515–526.
Bacher U, Schnittger S, Kern W, Weiss T, Haferlach T, Haferlach C . Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category. Ann Hematol 2009; 88: 1207–1213.
Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385–4395.
Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30: 820–829.
Wang SA, Abruzzo LV, Hasserjian RP, Zhang L, Hu Y, Zhang Y et al. Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. Leuk Res 2011; 35: 351–357.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.
Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53–59.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lympoid Tissues. IARC: Lyon, France, 2008.
Thol F, Kade S, Schlarmann C, Löffeld P, Morgan M, Krauter J et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119: 3578–3584.
Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384–1395.
Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012; 30: 3376–3382.
Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C . The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL-an analysis of 3307 cases. Leukemia 2016; 31: 705–711.
Acknowledgements
We thank all co-workers at the MLL Munich Leukemia Laboratory for their technical assistance, and all physicians for providing and caring for patients as well as collecting data.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
CH, WK and TH declare part ownership of MLL Munich Leukemia Laboratory. AS and MM are employed by MLL Munich Leukemia Laboratory.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Stengel, A., Kern, W., Meggendorfer, M. et al. MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations. Leukemia 31, 1995–1997 (2017). https://doi.org/10.1038/leu.2017.180
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.180
- Springer Nature Limited
This article is cited by
-
Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes
International Journal of Hematology (2018)
-
Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q)
Blood Cancer Journal (2017)